Treatment of oncological and hematological diseases in HIV infection
https://doi.org/10.17650/1818-8346-2023-18-3-125-133
Abstract
Oncological and hematological diseases associated with HIV infection continue to cause discussions among foreign and domestic researchers, clinicians, doctors, medical workers. The ongoing world globalization and modernization, environmental degradation have a detrimental effect on the health of citizens, which can be seen in virus mutations, high morbidity and a decrease in the social level in the Russian Federation and in the world. Oncological and hematological diseases associated with HIV infection are growing in the Russian Federation, but scientists do not stop at the results achieved, improving methods, treatment and therapy. As part of this study a statistical analysis of oncological and hematological diseases associated with HIV infection for 3 years (2019–2021) in Russia is carried out in order to trace the percentage of the medicine’s level, treatment’s effectiveness and deaths. A detailed analysis shows the decrease in deaths from HIV infection which pays attention the work of specialists in the Russian Federation.
The purpose of this study is to identify a key method for the treatment of oncological and hematological diseases in HIV infection in Russia.
The objective is to study the effectiveness of existing methods of treatment.
Research methods – clinical, functional, microbiological and morphological.
Supporting agencies: The work was performed without external funding
About the Authors
S. V. Lushchevich
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
119991
Build. 2, 8 Trubetskaya St.
Moscow
V. D. Litvinov
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
119991
Build. 2, 8 Trubetskaya St.
Moscow
References
1. Ptushkin V.V. Anemias and iron deficiency in cancer patients. Klinicheskaya onkogematologiya = Clinical Oncohematology 2013;6(1):91–6. (In Russ.).
2. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
3. State of oncological care in Russia in 2020. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 239 p. (In Russ.).
4. – F. Cancer (oncological diseases). ZDRAV. EXPERT. Medtech portal. (In Russ.). Available at: https://zdrav.expert/index.php/%D0%A1%D1%82%D0%B0%D1%82%D1%8C%D1%8F:%D0%A0%D0%B0%D0%BA_(%D0%BE%D0%BD%D0%BA%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F)
5. Pivnik A.V., Seregin N.V., Parkhomenko Yu.G. et al. Lymphomas in HIV-infected patients: literature review. Klinicheskaya onkogematologiya = Clinical Oncohematology 2014;7(3):264–77. (In Russ.)
6. Kaprin A.D., Voronin E.E., Rassokhin V.V. et al. Malignant neoplasms associated with HIV infection. Problems and solutions (problem outline). Sovremennaya onkologiya = Journal of Modern Oncology 2021;23(3):502–7. (In Russ.). DOI: 10.26442/18151434.2021.3.201041
7. Babicheva L.G. Review of the 1<sup>st</sup> Conference “Diagnosis and treatment of oncological and hematological diseases in HIV infection. Confident in the present – without fear in the future”. Onkogematologiya = Oncohematology 2022;17(4):138–57. (In Russ.). DOI: 10.17650/1818-8346-2022-17-4-138-157
8. Inoyatova F.I., Kadyrkhodjaeva Kh.M., Inogamova G.Z. et al. Some aspects of the transport system of iron metabolism depending on the degree of iron overload syndrome in children with chronic hepatitis B. Detskie infektsii = Children’s Infections 2019;18(1): 17–21. (In Russ.). DOI: 10.22627/2072-8107-2019-18-1-17-21
9. Rassokhin V.V., Nekrasova A.V., Mikhailova N.B. Malignant tumors in HIV patients. Epidemiology, pathogenesis, and variability. Part 1. VICH-infektsiya i immunosupressii = HIV Infection and Immunosuppressive Disorders 2017;9(1):7–21. (In Russ.) DOI: 10.22328/2077-9828-2017-9-1-7-21
10. Chelysheva E.Yu., Lazareva O.V., Turkina A.G. et al. Observation in a treatment-free remission in chronic myeloid leukemia patients with a stable deep molecular response in the Russian portion of the international multicenter population based study EUTOS PBS. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2022;67(3):351–66. (In Russ.). DOI: 10.35754/0234-5730-2022-67-3-351-366
11. Burg G., Kempf W., Kazakov D.V. et al. Pyogenic lymphoma of the skin: A peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol 2003;148(3):580–6. DOI: 10.1046/j.1365-2133.2003.05248.x
12. Castillo J., Pantanowitz L., Dezube B.J. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008;83(10):804–9. DOI: 10.1002/ajh.21250
13. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Letters 2011;305(2): 163–74. DOI: 10.1016/j.canlet.2011.03.003
14. Chang E., Sabichi A.L., Kramer J.R. et al. Nivolumab treatment for cancers in the HIV-infected population. J Immunother 2018;41(8):379–83. DOI: 10.1097/CJI.0000000000000240
15. Chen Y.B., Rahemtullah A., Hochberg E. Primary effusion lymphoma. Oncologist 2007;12(5):569–76. DOI: 10.1634/theoncologist.12-5-569
16. Guech-Ongey M., Simard E.P., Anderson W.F. et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010;116(25):5600–4. DOI: 10.1182/blood-2010-03-275917
17. Colomo L., Loong F., Rives S. et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28(6):736–47. DOI: 10.1097/01.pas.0000126781.87158.e3
18. Dupin N., Diss T.L., Kellam P. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95(4):1406–12.
19. Guihot A., Marcelin A.G., Massiani M.A. et al. Drastic decrease of the HIV reservoir in a patient treated with Nivolumab for lung cancer. Ann Oncol 2018;29(2):517–8. DOI: 10.1093/annonc/mdx696
20. Kolesnikova M.A., Nechunaeva I.N., Popova M.O., Pospelova T.I. Epidemiological features and efficacy of treatment in HIVassociated lymphomas. Available at: https://cyberleninka.ru/article/n/epidemiological-features-and-efficacy-of-treatment-in-hiv-associated-lymphomas?ysclid=lmhgbhxtdz42198242.
21. Rezk S.A., Weiss L.M. Epstein–Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007;38(9):1293–304. DOI: 10.1016/j.humpath.2007.05.020
22. Rodrigues L.K.E., Klencke B.J., Vin-Christian K. et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002;138(6):765–70. DOI: 10.1001/archderm.138.6.765
23. Sandoval-Sus J.D., Mogollon-Duffo F., Patel A. et al. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer 2017;5:49. DOI: 10.1186/s40425-017-0252-3
24. Simonelli C., Spina M., Cinelli R. et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003;21(21):3948–54. DOI: 10.1200/JCO.2003.06.013
25. Spina M., Berretta M., Tirelli U. Hodgkin’s disease in HIV. Hematol Oncol Clin North Am 2003;17(3):843–58. DOI: 10.1016/s0889-8588(03)00046-7
26. Wilkins K., Turner R., Dolev J.C. et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006;54(2):189–206. DOI: 10.1016/j.jaad.2004.11.060
27. Talat N., Schulte K.M. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist 2011;16(9):1316–24. DOI: 10.1634/theoncologist.2011-0075
28. Vaccher E., Spina M., Tirelli U. Clinical aspects and management of Hodgkin’s disease and other tumours in HIV-infected individuals. Eur J Cancer 2001;37(10):1306–15. DOI: 10.1016/s0959-8049(01)00122-8
29. Mounier N., Spina M., Spano J.P. Hodgkin lymphoma in HIV positive patients. Curr HIV Res 2010;8(2):141–6. DOI: 10.2174/157016210790442704
30. Rogacheva Y.A., Popova M.O., Nekrasova A.V. et al. Nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas. Abstracts Clinical practice (including toxicities) 2018;29(Suppl_10):x20–1. DOI: 10.1093/annonc/mdy486.011. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)32673-0/fulltext.
31. Popova M.O., Rogacheva Y.A., Nekrasova A.V. et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of a single center (CIC725) matched case-control study. Cell Ther Transplant 2017;6(4):42–51. DOI: 10.18620/ctt-1866-8836-2017-6-4-42-51
32. Daminov T.A., Tuychiev L.N., Khudaykulova G.K., Rakhmatullaeva S.B. Etiological structure of anemia in HIVinfected children. Detskie infektsii = Children’s Infections 2019;18(2):20–3. (In Russ.) DOI: 10.22627/2072-8107-2019-18-2-20-23
33. Kulibaba Т.G., Pchelin I.Yu., Slepykh L.A. Characteristic features of anemic syndrome in oncological patients. Juvenis Scientia 2018;(9):10–6. (In Russ.). DOI: 10.32415/jscientia.2018.09.02.
34. Moiseev S.V. Capacities of somatostatin analogues to treat castration-resistant prostate cancer. Onkologiya. Zhurnal im. P. A. Gertsena = P. A. Herzen Journal of Oncology 2012;1(1):77–82. (In Russ.).
Review
For citations:
Lushchevich S.V., Litvinov V.D. Treatment of oncological and hematological diseases in HIV infection. Oncohematology. 2023;18(3):125-133. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-3-125-133
Views:
4379
Email this article 